A detailed history of Vanguard Group Inc transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,565,487 shares of ELDN stock, worth $6.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,565,487
Previous 1,104,395 41.75%
Holding current value
$6.26 Million
Previous $2.92 Million 33.72%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.41 - $3.19 $1.11 Million - $1.47 Million
461,092 Added 41.75%
1,565,487 $3.9 Million
Q2 2024

Aug 13, 2024

BUY
$1.57 - $3.12 $212,380 - $422,054
135,274 Added 13.96%
1,104,395 $2.92 Million
Q1 2024

May 10, 2024

BUY
$1.54 - $2.13 $421,502 - $582,987
273,703 Added 39.36%
969,121 $2 Million
Q4 2023

Feb 14, 2024

BUY
$1.12 - $1.86 $23,405 - $38,870
20,898 Added 3.1%
695,418 $1.25 Million
Q3 2023

Nov 14, 2023

SELL
$1.14 - $1.66 $5,742 - $8,361
-5,037 Reduced 0.74%
674,520 $924,000
Q4 2022

Feb 10, 2023

BUY
$2.17 - $2.75 $681 - $863
314 Added 0.05%
679,557 $1.55 Million
Q1 2022

May 13, 2022

BUY
$3.06 - $4.89 $29,201 - $46,665
9,543 Added 1.42%
679,243 $2.68 Million
Q4 2021

Feb 14, 2022

SELL
$4.02 - $6.07 $3,268 - $4,934
-813 Reduced 0.12%
669,700 $2.95 Million
Q3 2021

Nov 12, 2021

BUY
$5.94 - $8.46 $2.74 Million - $3.9 Million
460,763 Added 219.67%
670,513 $4.14 Million
Q2 2021

Aug 13, 2021

BUY
$7.62 - $11.75 $1.6 Million - $2.46 Million
209,750 New
209,750 $1.66 Million

Others Institutions Holding ELDN

About Eledon Pharmaceuticals, Inc.


  • Ticker ELDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,756,800
  • Market Cap $55M
  • Description
  • Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...
More about ELDN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.